Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Charles Fruchart

Showing results (11-20 of 167) with videos related to

Pageof 17
Sort By:
Current Opinion in Lipidology|November 21, 2002
HDL and triglyceride as therapeutic targetsJean-Charles Fruchart, Patrick Duriez
Drugs of Today (Barcelona, Spain : 1998)|March 3, 2006
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolismJean-Charles Fruchart, Patrick Duriez
Therapeutic Advances in Chronic Disease|December 20, 2012
Reducing vascular events risk in patients with dyslipidaemia: an update for cliniciansMichel P Hermans, Jean-Charles Fruchart
Current Opinion in Lipidology|October 3, 2019
SPPARM alpha: the Lazarus effectJean-Charles Fruchart, Raul D Santos
Current Atherosclerosis Reports|August 13, 2003
Peroxisome proliferator activated receptors and strokeJean-Charles Fruchart, Régis Bordet, Patrick Duriez
Current Opinion in Pharmacology|September 16, 2006
PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndromeCatherine Fiévet, Jean-Charles Fruchart, Bart Staels
Nature Clinical Practice. Endocrinology & Metabolism|January 24, 2007
Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptorsPhilippe Gervois, Jean-Charles Fruchart, Bart Staels
Current Opinion in Lipidology|September 23, 2003
Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and functionGiulia Chinetti, Jean-Charles Fruchart, Bart Staels
Frontiers in Bioscience : a Journal and Virtual Library|May 9, 2007
Genetically-engineered animals as research models for atherosclerosis: their use for the characterization of PPAR agonists in the treatment of cardiometabolic disordersCatherine Fievet, Jean-Charles Fruchart, Bart Staels
Circulation|June 17, 2004
Atherogenic lipoprotein particles in atherosclerosisRafael Carmena, Patrick Duriez, Jean-Charles Fruchart
Pageof 17

Showing results (11-20 of 167) with videos related to

Sort By:
Pageof 17
Current Opinion in Lipidology|November 21, 2002
HDL and triglyceride as therapeutic targetsJean-Charles Fruchart, Patrick Duriez
Drugs of Today (Barcelona, Spain : 1998)|March 3, 2006
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolismJean-Charles Fruchart, Patrick Duriez
Therapeutic Advances in Chronic Disease|December 20, 2012
Reducing vascular events risk in patients with dyslipidaemia: an update for cliniciansMichel P Hermans, Jean-Charles Fruchart
Current Opinion in Lipidology|October 3, 2019
SPPARM alpha: the Lazarus effectJean-Charles Fruchart, Raul D Santos
Current Atherosclerosis Reports|August 13, 2003
Peroxisome proliferator activated receptors and strokeJean-Charles Fruchart, Régis Bordet, Patrick Duriez
Current Opinion in Pharmacology|September 16, 2006
PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndromeCatherine Fiévet, Jean-Charles Fruchart, Bart Staels
Nature Clinical Practice. Endocrinology & Metabolism|January 24, 2007
Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptorsPhilippe Gervois, Jean-Charles Fruchart, Bart Staels
Current Opinion in Lipidology|September 23, 2003
Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and functionGiulia Chinetti, Jean-Charles Fruchart, Bart Staels
Frontiers in Bioscience : a Journal and Virtual Library|May 9, 2007
Genetically-engineered animals as research models for atherosclerosis: their use for the characterization of PPAR agonists in the treatment of cardiometabolic disordersCatherine Fievet, Jean-Charles Fruchart, Bart Staels
Circulation|June 17, 2004
Atherogenic lipoprotein particles in atherosclerosisRafael Carmena, Patrick Duriez, Jean-Charles Fruchart
Pageof 17